Novodiag® Bacterial GE+, a New Diagnostic Test for on-Demand Detection of Bacterial Pathogens
Mobidiag, a Finnish molecular diagnostics company, today announced the launch of Novodiag® Bacterial GE+, a molecular diagnostic test for the simultaneous detection of most common enteric pathogens directly from stool samples. Compatible with the fully automated Novodiag® system launched at the end of 2017, this new disposable cartridge allows direct analysis of a patient sample and delivers comprehensive results in about an hour, compared to days with currently used culture methods.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180416005997/en/
Novodiag® Bacterial GE+, molecular diagnostic test for on-demand detection of bacterial pathogens (Photo: Mobidiag)
“The new Novodiag Bacterial GE+ cartridge can identify dozens of targets, including the majority of bacteria causing diarrhea. Thanks to its simplified and optimized workflow, our fully automated Novodiag solution can support early decision making prior to any treatment delivery and improve patient care by managing infections accordingly” explains Tuomas Tenkanen. “We are very proud to now offer the first syndromic test compatible with our Novodiag system. Our ambition is to make accessible one of the most relevant range of test panels. We are currently working on extending our product line and address among others the detection of antibiotic resistances to improve the correct use of antibiotics”.
Novodiag® Bacterial GE+ test is now available directly through Mobidiag and local distributors. For more information, visit our product page.
The Novodiag solution allows direct analysis of a patient sample placed in a disposable cartridge and delivers comprehensive results in about an hour. Combining qPCR and microarray technologies, Novodiag offers an all in one solution for on-demand targeted and syndromic testing.
This molecular diagnostic solution offers an easy to use and cost-efficient method, with very limited hands-on-time and without the need for much technical expertise. Novodiag is suitable for all test volumes and on demand testing for clinical laboratories.
Learn more about Novodiag.
About Mobidiag Ltd.
Established in 2000, Mobidiag develops and commercializes innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo, Finland, with an R&D center in France and subsidiaries in UK and Sweden.
Combining Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive line of products for fast, reliable and cost-efficient diagnostics for infectious diseases and antibiotic resistances. Mobidiag is able to cover all laboratories requirements no matter their size, throughput and centralized/ decentralized organization.
To learn more, visit mobidiag.com
Dorothee Allard, +33 1 55 25 17 13
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
MC2 Therapeutics Announces Topline Results Showing a Favorable Safety Profile and Reduction in Corneal Staining for MC2-03 in Dry Eye Patients with Moderate to Severe Keratitis23.10.2018 09:30 | Tiedote
MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company, today announced topline results from the MC2-03-C1 Northern Lights Phase 2 trial evaluating the safety and efficacy of MC2-03 (PADciclo™) in moderate-to-severe dry eye (DED) patients. MC2-03 is an eye drop containing ciclosporin (CsA) formulated using MC2 Therapeutics’ proprietary PAD™ Technology to enable improved penetration into ocular tissues without the use of excipients that can cause ocular safety concerns. Topline results will be presented at the Ophthalmology Innovation Summit (OIS) in Chicago on October 25th, 2018. In this randomized, double-masked, parallel arms, controlled six-month trial enrolling 263 adult patients, two active treatment arms (MC2-03 0.06% CsA and MC2-03 0.03% CsA) were compared to two control arms (MC2-03 vehicle and lubricant) as an add-on therapy to a standard-of-care lubricant. The trial was powered to evaluate safety and efficacy of the individual treatment arms, and to potential
Secure Networks are Key to IoT Revolution, Says NTT Communications23.10.2018 09:00 | Tiedote
While the Internet of Things (IoT) has the potential to drive the next wave of online innovation, it needs to be grounded on secure networks that prevent cyber criminals from hacking into the myriad of IoT-enabled devices that they are increasingly connecting. This is just one of the top line industry assessments provided today by NTT Communications Corp. (NTT Com), a company that owns and operates one of the world’s largest IP backbones and is the data and global IP service arm of Fortune 500 telecom leader NTT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181022005985/en/ Michael Wheeler, executive vice president of NTT Communications Global IP Network at NTT America (Photo: Business Wire) IoT Has Massive Potential to Innovate, But First Needs to Be Secure “The Internet of Things revolution has tremendous potential to enhance and improve daily life by enabling our devices to connect and communicate with our other devices
NTT Communications Rated First for Growth in Customer Loyalty23.10.2018 09:00 | Tiedote
NTT Communications Corporation (NTT Com), the information and communications technology (ICT) solutions business within the NTT Group (TOKYO: 9432) announced today that it earned the ‘valued partner’ accolade in 5 out of 12 categories according to the second edition of Digital Zenith Benchmark, a report recently published by Ocean82 that measures customer-centric evolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181022005018/en/ Ocean82 Crystal Ball DIZEME (Graphic: Business Wire) A total of 866 people, who work for large and multi-national enterprises, were interviewed about their experiences with global service providers, generating about 1,000 evaluations and 6,000 points of data, over the last 12 months. The data was analyzed using an algorithm to calculate a cooperation coefficient, which is denoted by DZ and named DIZEME. The report can be viewed here. The ‘valued partner’ benchmark represents the point at whic
Nine-Month Figures for 2018: Sartorius Continues to Grow by Double Digits23.10.2018 08:00 | Tiedote
Sartorius, a leading international partner of biopharmaceutical research and the industry, continued on the growth track, with double-digit gains in sales revenue and earnings. “In the first nine months of 2018, Sartorius achieved excellent organic growth,” said Dr. Joachim Kreuzburg, Chief Executive Officer. “This applies particularly to the Bioprocess Solutions Division, which grew dynamically across all product categories and geographies. For the Lab Products & Services Division, growth in the third quarter was below our expectations due to softer demand in Europe. At the Group level, however, this effect will be largely compensated for by the strong development of our bioprocess business so that we confirm our ambitious full-year forecast.” Business development of the Sartorius Group In the first nine months of 2018, Sartorius increased its sales revenue by 13.4% in constant currencies to 1,153.7 million euros (reported: +10.9%). The majority of growth was achieved organically, whi
Philip Morris International Launches Next Generation of IQOS, the World’s Leading Heated Tobacco Product23.10.2018 05:30 | Tiedote
In its passion and drive to provide better choices to people who smoke, Philip Morris International Inc. (“PMI”) (NYSE: PM), the global leader in smoke-free innovation and science, has launched the next generation of IQOS. The new IQOS 3 and IQOS 3 MULTI integrate extensive consumer insights and feedback to improve design and user experience while maintaining signature taste, sensory attributes and ritual—all underpinned by strong scientific substantiation. The new versions aim to further encourage a growing number of smokers to switch, to the benefit of their health, public health and, ultimately, society. The new iterations were launched today in Tokyo, Japan—the country considered the birthplace of IQOS. The iconic brand offers the best in taste and satisfaction in the category, and almost 6 million adult smokers have already quit cigarettes—with more than half of those in Japan. “Our dream was to create a better alternative for smokers, and IQOS has made this dream a reality; it’s
Logitech Delivers Record Q2 Sales and Double-Digit Profit Growth23.10.2018 04:00 | Tiedote
Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the second quarter of Fiscal Year 2019. Q2 sales were $691 million, up 9 percent in US dollars and 10 percent in constant currency, compared to Q2 of the prior year. Q2 GAAP operating income reached $65 million, compared to $59 million in the same quarter a year ago. Q2 GAAP earnings per share (EPS) grew 15 percent to $0.38, compared to $0.33 in the same quarter a year ago. Q2 non-GAAP operating income grew 18 percent to $85 million, compared to $71 million in the same quarter a year ago. Q2 non-GAAP EPS grew 26 percent to $0.49, compared to $0.39 in the same quarter a year ago. Q2 cash flow from operations was $85 million, up 24 percent compared to Q2 of the prior year. Cash flow from operations for the fiscal year to date was $97 million, compared to $67 million for the same period a year ago. “Q2 showcased the power and diversity of our portfolio,” said Bracken Darrell, Logitech president and chi
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme